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Abstract
Background: The development of efficacious alternatives to antimicrobial growth promoters (AGP) in livestock
production is an urgent issue, but is hampered by a lack of knowledge regarding the mode of action of AGP. The
belief that AGP modulate the intestinal microbiota has become prominent in the literature; however, there is a lack
of experimental evidence to support this hypothesis. Using a chlortetracycline-murine-Citrobacter rodentium model,
the ability of AGP to modulate the intestinal immune system in mammals was investigated.
Results: C. rodentium was transformed with the tetracycline resistance gene, tetO, and continuous oral
administration of a non-therapeutic dose of chlortetracycline to mice did not affect densities of C. rodentium CFU
in feces throughout the experiment or associated with mucosal surfaces in the colon (i.e. at peak and late
infection). However, chlortetracycline regulated transcription levels of Th1 and Th17 inflammatory cytokines in a
temporal manner in C. rodentium-inoculated mice, and ameliorated weight loss associated with infection. In mice
inoculated with C. rodentium, those that received chlortetracycline had less pathologic changes in the distal colon
than mice not administered CTC (i.e. relative to untreated mice). Furthermore, chlortetracycline administration at a
non-therapeutic dose did not impart either prominent or consistent effects on the colonic microbiota.
Conclusion: Data support the hypothesis that AGP function by modulating the intestinal immune system in
mammals. This finding may facilitate the development of biorationale-based and efficacious alternatives to AGP.
Keywords: Antimicrobial growth promoters, AGP, chlortetracycline, Citrobacter rodentium, immunomodulation
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Background
The in-feed administration of non-therapeutic doses of
antimicrobial growth promoters (AGP) has been suc-
cessfully used to promote animal growth for more than
60 years [1]. Unfortunately, the indiscriminate use of
AGP [2] has contributed to the emergence of antimicro-
bial resistance (AMR) in zoonotic pathogens [3-5], and
the European Union (EU) implemented a precautionary
ban on administration of all AGP (i.e. at non-therapeu-
tic doses) to livestock [6,7]. The AGP ban in the EU
increased the therapeutic administration of antimicrobial
agents [6], as well as the cost of animal production, and
resulted in a general decline in livestock production [8].
A recent guidance document issued by the United States
Food and Drug Administration recommended restric-
tions that would limit the use of AGP [9]. Thus, it is
anticipated that an AGP ban will progressively be
imposed in North America, adversely affecting the sus-
tainability of livestock production. We contend that elu-
cidating the mode of action of AGP will facilitate the
development of suitable, efficacious, and biorationale-
based alternatives to AGP to enhance livestock
production.
The literature on the mode of action of AGP is scarce;
the most widely accepted hypothesis is that AGP modu-
late the intestinal microbiota [10,11]. The ‘microbiota
modulation hypothesis’ suggests that AGP reduces
microbial competition for nutrients, decreases
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production of growth-depressing metabolites by intest-
inal microorganisms, suppresses opportunistic patho-
gens, and results in a thinner intestinal wall, which
increases nutrient assimilation [10]. Despite widespread
acceptance, definitive evidence to support the micro-
biota modulation hypothesis is lacking. The consistency
of growth-promotion effects imparted by AGP on var-
ious animal species possessing highly dissimilar intest-
inal microbiota coupled with low concentrations at
which AGP are administered (i.e. at doses less than the
minimum inhibitory concentration for most pathogens)
challenges the validity of the microbiota modulation
hypothesis of AGP action [12]. Since many antimicrobial
agents have anti-inflammatory and immunomodulatory
properties [13], an alternate hypothesis for the mode of
action of AGP was recently proposed [12], namely, that
AGP decrease immunologic stress in the host [14]. The
intestinal mucosa is in a constant state of “physiologic
inflammation” [15], attributable to the close contact
between the intestinal mucosa and the microbiota [16].
By decreasing immunologic stress in the intestinal
mucosa, AGP would reduce the catabolic cost to the
host, thereby increasing the energy available for muscle
development and improving growth performance [17].
The ‘immunomodulation hypothesis’ for AGP action is
consistent with the growth-promotion effects observed
when AGP is administered to animals possessing very
disparate intestinal microbiota [12]. To our knowledge,
the validity of the immunomodulation hypothesis for
AGP action has not been formally tested. Thus, we for-
mulated and tested the hypothesis that non-therapeutic
concentrations of a model AGP administered orally to
mammals will modulate enteric immune responses.
To test the immunomodulation hypothesis of AGP
action we used chlortetracycline (CTC) as a model
AGP; CTC is a commonly used AGP in North Ameri-
can livestock production, and at therapeutic concentra-
tions, tetracyclines are known to modulate immune
responses [18]. Given the inherent genetic and microbial
variability of livestock species, mice were used as a
mammalian model. To test the immunomodulation
hypothesis it was necessary to experimentally induce
inflammation within the intestine of mice, and to do so,
we utilized Citrobacter rodentium. This bacterium is a
non-invasive, attaching/effacing bacterial pathogen
which causes a self-limiting acute colitis in immuno-
competent laboratory mice [19,20], and has been widely
accepted as a robust in vivo model system to assess
host-pathogen interactions [20,21]. C. rodentium colo-
nizes the apical surface of the large intestinal mucosa,
causing mucosal hyperplasia, localized microvilli loss,
and mucosal inflammation [22]. Using the CTC-murine-
C. rodentium model, specific experimental objectives
were to: determine the temporal impact of CTC on host
responses in mice inoculated or not inoculated with C.
rodentium; and concomitantly measure the effects of
CTC and/or C. rodentium on the composition of the
mucosa-associated colonic microbiota.
Results
Residual CTC in feces
Residual CTC was detected in acidic extracts of feces
from mice given CTC, with no significant difference
between the CTC and CTC+CR treatments. Mean resi-
dual CTC value was 63.9 ± 6.6 μg/g of feces for CTC
treatment mice, and 63.3 ± 9.6 μg/g of feces for CTC
+CR treatment mice. No CTC was detected in acidic
extracts from feces of mice not given CTC.
Intestinal colonization by C. rodentium and tetO temporal
occurrence
Considerable numbers of C. rodentium cells were recov-
ered from feces and colonic mucosa of inoculated mice
throughout the experiment (Figure 1). No C. rodentium
cells were recovered from uninoculated mice. Densities
of C. rodentium cells recovered from feces and mucosal
surfaces changed over time (P < 0.001); population sizes
peaked between 9 and 11 days p.i., and decreased there-
after until no cells were detected 21 days p.i. (Figure 1).
Relative to the CR treatment, administration of CTC did
not affect (P = 0.81) densities of C. rodentium CFU in
murine feces (P = 0.84) at all sample times (Figure 1A).
With the exception of the 3 day p.i. sample (P < 0.05),
there also was no difference (P > 0.05) between treat-
ments in densities of C. rodentium CFU associated with
colonic mucosa (Figure 1B).
All C. rodentium cells recovered and evaluated from
the feces of CTC+CR treatment mice had the tetO gene
until day 19 p.i. All C. rodentium cells recovered and
evaluated from CR treatment mice had the tetO gene
until day 9 p.i.; 50% of cells had the tetO gene at days
11 and 13 p.i., and no cells possessed the tetO gene at
days 15, 17, 19, and 21 p.i.
Signs of disease
Mice inoculated with C. rodentium (i.e. CR treatment
and CTC+CR treatment) did not exhibit clinical signs
of disease. However, CR treatment mice weighed less (P
< 0.05) than Control treatment mice on days 7, 10, and
14 p.i. (Figure 2). Mice inoculated with C. rodentium
and given CTC (i.e. CTC+CR treatment) weighed less
(P < 0.05) than Control mice only on day 10 p.i., and
weighed more (P < 0.05) than CR treatment mice on
day 14 p.i. There was no difference (P > 0.05) in body
weight between Control and CTC treatment mice.
However, an apparent trend of CTC treated mice being
heavier than Control animals was observed on day 17
and 21.
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Gross and histopathology
Thickening of the distal colon was observed in four of
the six CR and CTC+CR treatment mice at day 8 p.i.
Conspicuous thickening of the distal colon was evident
14 days p.i. in all CR treatment mice and approximately
two-thirds of CTC+CR treatment mice. All C. roden-
tium-inoculated mice (i.e. CR and CTC+CR treatments)
had colonic pathology (detected histologically) relative
to Control mice (Tables 1-2). The intensity of inflamma-
tion increased throughout the infection period with the
highest scores of inflammation observed at 14 days p.i.
Notably, transmural inflammation was observed in the
colons of CR treatment mice at day 14 p.i. Infection by
C. rodentium increased (P < 0.05) crypt height, which
was first evident 8 days p.i., and crypt height remained
significantly different relative to Control and CTC
Figure 1 Mean quantities of C. rodentium cells (CFU/g) in feces (A) and associated with colonic mucosa (B) of mice inoculated with the
bacterium and given CTC (CTC+CR) or water alone (CR). Vertical lines associated with individual markers at each sample time indicate
standard error of the mean (n = 3). *Values differ (P < 0.05).
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treatment mice throughout the remainder of the experi-
mental period (Figure 3). Crypt height reached a maxi-
mum 14 days p.i. (P < 0.05, Figure 3). Crypt height was
not different (P > 0.05) between CTC+CR and CR treat-
ments, nor between Control and CTC treatments. Total
pathology scores and individual category scores repre-
senting tissue changes did not differ (P > 0.05) between
treatments at day 3 p.i. (Table 2). At subsequent sample
times, there was no difference (P > 0.05) between Control
and CTC treatments, nor between CTC+CR and CR
treatments. At day 8 p.i., total score and all individual
category scores differed (P < 0.05) for CTC+CR and CR
treatments relative to the Control treatment. Although
there was no significant difference between CTC+CR and
CR treatments, there was a trend for decreased patholo-
gic changes in CTC+CR treatment at later stages of
infection. For example, there was no difference (P > 0.05)
in mitotic activity scores for the CTC+CR relative to the
Control treatment at 14 days p.i., whereas mitotic activity
was higher (P < 0.05) for the CR treatment relative to the
Control treatment (Table 2). At day 21 p.i., crypt height,
inflammatory infiltrates, and total pathology scores
Figure 2 Mean change in body weight (%) of mice. Treatments are: (Control) mice not inoculated with C. rodentium or administered CTC;
(CTC) mice not inoculated with C. rodentium but administered CTC; (CR) mice inoculated with C. rodentium but not administered CTC; and (CTC
+CR) mice inoculated with C. rodentium and administered CTC. Vertical lines associated with individual markers at each sample time indicate
standard error of the mean (n = 3). *P < 0.05 when compared with Control mice; **P < 0.05 when compared with Control or CTC treatment
mice; ***P < 0.05 when compared with Control, CTC or CTC+CR treatment mice.
Table 1 Histopathological scores of the distal colons of mice
Control CTC CR CTC+CR
Cat/Day 3 8 14 21 3 8 14 21 3 8 14 21 3 8 14 21
EHa 0b 0 0 0-1 0-1 0-1 0-1 0 0-1 1-2 2-4 1-2 0 2 1-3 0-1
CH 0 0 0 0 0-1 0 0-1 0 0-1 2 2-4 1-2 0-1 2-3 1-3 0-2
EI 0 0 0 0 0-1 0 0 0 0 3-4 2-3 0-2 0 3 0-4 0-2
II 0 0-1 0 0 0 0 0 0 0 2-4 3-4 1-4 0 3-4 1-4 0-2
MA 0 0-1 0 0 0 0 0 0 0 2-3 3 1 0-1 2-3 1-3 1-2
GC 0 0 0 0 0 0 0 0 0 1-2 2-3 0-1 0 1-2 0-3 0
Total 0 0-1 0 0-1 0-2 0-2 0-2 0-1 0-1 13-15 16-20 4-12 0-1 14-16 4-20 1-9
aPathology categories (Cat): EH, epithelial hyperplasia; CH, crypt height; EI, epithelial injury; II, inflammatory infiltrates; MA, mitotic activity; GC, globlet cell
depletion. Total score corresponds to the sum of scores of all categories.
bRange of scores were: 0 to 4 for EH, CH, EI, II; 0 to 3 for MA, GC; 0 to 22 for Total.
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differed (P < 0.05) between the Control and CR treat-
ments, but did not differ (P > 0.05) between the Control
and CTC+CR treatments.
Cytokine gene expression
Concentrations of Th1- (IFN-g, TNF-a, and IL-2), Th2-
(IL-4), Th17- (IL-17A, IL-22, IL-1b, and IL-6), and
Treg- (IL-10 and TGF-b1) cytokine mRNA in colonic
tissues was quantified. C. rodentium infection increased
(P < 0.05) concentrations of Th1 cytokine mRNA
(Figure 4A-B) and Th17 cytokine mRNA (Figure 4D-G)
at 8 and 14 days p.i. Transcript levels of IL-2 were
differentially elevated (P < 0.05) in inoculated mice at 21
days p.i. only (Figure 4C). However, no significant
changes in transcript levels of genes associated with Th2
(Figure 4H) and Treg (Figure 4I-J) cytokines were
detected in inoculated mice. Mice from the CTC treat-
ment did not show differential mRNA expression for
most cytokines relative to the Control treatment. How-
ever, there was a two fold decrease (P < 0.05) in the
concentration of TGF-b mRNA (Figure 4J) and a near
two fold increase (P < 0.05) in IL-4 mRNA (Figure 4H)
in CTC treatment mice on day 21 p.i. CTC also
increased (P < 0.05) transcript levels of IL-2 (Figure 4C).
Table 2 Pairwise analyses of histopathological changes in the distal colons of micea
Control vs CR Control vs CTC+CR CR vs CTC+CR
Cat/Day 3 8 14 21 3 8 14 21 3 8 14 21
EHb 0.317 0.034* 0.076 0.090 1.000 0.025* 0.075 0.456 0.317 0.317 0.261 0.197
CH 0.317 0.025* 0.076 0.034* 0.317 0.039* 0.068 0.114 1.000 0.317 0.486 0.796
II 1.000 0.046* 0.068 0.037* 1.000 0.043* 0.068 0.121 1.000 0.637 0.814 0.261
EI 1.000 0.034* 0.068 0.114 1.000 0.025* 0.197 0.317 1.000 0.317 0.816 0.456
MA 1.000 0.043* 0.045* 0.025* 0.317 0.043* 0.068 0.034* 0.317 0.456 0.317 0.317
GC 1.000 0.034* 0.068 0.317 1.000 0.034* 0.182 1.000 1.000 1.000 0.796 0.317
Total 0.114 0.046* 0.037* 0.046* 0.114 0.046* 0.037* 0.072 1.000 0.261 1.000 0.513
aPairwise comparisons were conducted using the Kruskal Wallis non-parametric test. P values marked with an asterisk are significantly different (P = 0.05).
bPathology categories (Cat): EH, epithelial hyperplasia; CH, crypt height; EI, epithelial injury; II, inflammatory infiltrates; MA, mitotic activity; GC, globlet cell
depletion. Total score corresponds to the sum of scores of all categories.
Figure 3 Mean colonic epithelial crypt height (μm). Treatments are: (Control) mice not inoculated with C. rodentium or administered CTC;
(CTC) mice not inoculated with C. rodentium but administered CTC; (CR) mice inoculated with C. rodentium but not administered CTC; and (CTC
+CR) mice inoculated with C. rodentium and administered CTC. Vertical lines associated with histogram bars indicate standard error of the mean
(n = 3). Histogram bars at individual times not indicated with the same letter differ (P < 0.05).
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In inoculated mice, CTC administration (i.e. CTC+CR
treatment) increased (P < 0.05) transcript levels of IFN-
g, TNF-a, and IL-22 genes (Figure 4A-B, Figure 5E),
and decreased (P < 0.05) transcript levels of the IL-1b
gene 8 days p.i. relative to the CR treatment (Figure 4F).
Furthermore, administration of CTC to inoculated mice
increased (P < 0.05) transcript levels of the IFN-g, and
decreased (P < 0.05) transcript levels of the TNF-a, IL-
17A, IL-22, and IL-1b genes 14 days p.i. relative to the
CR treatment (Figure 4A-B, Figure 4D-F). For Th17
cytokines, there was a trend for an initial increase in
transcript levels of IL-17A, IL-22, and IL-6 genes in
Figure 4 Relative mean mRNA expression (log [2-ΔCt + 1]) of cytokine genes in colonic tissues. Treatments are: (Control) mice not
inoculated with C. rodentium or administered CTC; (CTC) mice not inoculated with C. rodentium but administered CTC; (CR) mice inoculated with
C. rodentium but not administered CTC; and (CTC+CR) mice inoculated with C. rodentium and administered CTC. Vertical lines associated with
histogram bars indicated standard error of the means (n = 3). (A) IFN-g; (B) TNF-a; (C) IL-2; (D) IL-17A; (E) IL-22; (F) IL-1b; (G) IL-6; (H) IL-4; (I) IL-10;
(J) TGF-b. For each cytokine, histogram bars at individual times indicated by a different letter differ (P < 0.05).
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infected mice administered CTC (i.e. CTC+CR treat-
ment) relative to CR treatment mice (i.e. at day 8 p.i.)
(Figure 4D-E, Figure 4G). Thereafter (i.e. at day 14 p.i.),
transcript levels of IL-17A, IL-22, and IL-6 cytokine
genes tended to decrease differentially in CTC+CR
treatment mice relative to CR treatment mice. Tran-
script levels of IL-1b in CTC+CR mice remained lower
relative to CR treatment mice at both the peak and late
infection periods (Figure 4F).
Mucosa-associated bacterial communities
Diverse bacterial communities were observed in associa-
tion with mucosal surfaces of the colons of all mice,
regardless of treatment. The composition of bacterial
communities varied amongst individual animals; how-
ever, ordination of T-RFLP profiles by NMS analysis
revealed no obvious grouping of replicate mice within
treatments (not shown). Global comparisons revealed
the formation of unique (P < 0.05) community composi-
tions for the Control and CTC+CR treatments at 8 days
p.i., and for the CTC+CR and CR treatments at 21 days
p.i. (Table 3). The composition of the colonic micro-
biota in mice infected by C. rodentium and/or given
CTC differed (P < 0.05) from mice assigned to corre-
sponding control treatments, but this occurred periodi-
cally, and only at early and peak infection (Table 4).
Furthermore, differences were not consistent for both
treatments (i.e. for individual pairwise comparisons) and
this was attributed to variability amongst replicate ani-
mals. Based on NMS analysis, the microbiota of mice
administered CTC clustered only at day 3 p.i. (not
shown).
Discussion
Research regarding the use of AGP in agriculture and
animal production has predominantly focused on mea-
suring the prevalence of AMR in zoonotic pathogens
[4,5,23-25]. That giving AGP selects for resistance to
antimicrobials in bacteria has promulgated the belief
that AGP induce growth promotion in livestock as a
result of direct effects on the intestinal microbiota
[10,26]. However, there is a dearth of experimental evi-
dence to support the ‘microbiota modulation hypoth-
esis’. Furthermore, it was recently reported that AGP
administration did not significantly alter the intestinal
microbiota in pigs [27]. Antibiotics are anti-inflamma-
tory and immunomodulatory [13]; thus, AGP may func-
tion by modulating the immune system within the
intestine thereby providing a catabolic advantage to the
host [12]. To our knowledge this has never been tested.
We formulated the ‘immunomodulation hypothesis’ of
AGP action, and we used a CTC-murine-C. rodentium
model to test this hypothesis.
An antimicrobial agent is a growth promoter when
administered in/on the feed of food animals to promote
growth and enhance feed efficiency. Growth promoters
are usually administered in relatively low concentrations
(i.e. non-therapeutic), ranging from 2.5 to 125 mg kg-1
(ppm), depending on the compound and animal species
treated [28]. CTC is commonly used as an AGP for
mammalian livestock [29]. In the current study, a simu-
lated non-therapeutic dose of CTC was given to mice
with the dose extrapolated from that commonly used in
beef cattle. Measurable quantities of ingested CTC (and
its epimer, epi-CTC) are excreted in livestock feces [30].
Consistent with this finding, measurable CTC concen-
trations were excreted in the feces of all mice given
CTC. The experimental design required that mice be
continuously administered CTC (i.e. to mice assigned to
the CTC and CTC+CR treatments), necessitating that
the C. rodentium be transformed to have resistance to
CTC. Although tetracycline resistance determinants may
persist in the absence of selection pressure [31,32], the
plasmid-borne tetO gene transferred into C. rodentium
was less persistent in the mice not given CTC. However,
there was no significant difference between the CR and
CTC+CR treatments in shedding or mucosal coloniza-
tion by the bacterium at the peak, late, and clearance
stages of infection. Reasons for the significantly lower
numbers of C. rodentium associated with colonic
Table 3 Global analyses of T-RFLP community profilesa
Treatment
Day Control CTC CR CTC+CR
3 0.888 0.249 0.487 0.069
8 0.003* 0.708 0.287 0.033*
14 0.391 0.709 0.575 0.717
21 0.070 0.085 0.035* 0.035*
aP values marked with an asterisk are significantly different (P ≤ 0.05).
Table 4 Pairwise analyses of T-RFLP community profilesa
Day / Group
3 8 14 21
Treatment
Comparisons
A B A B A B A B
Control (A) vs
CTC (B)
0.797 0.021* 0.025* 0.732 0.338 0.542 0.308 0.267
Control (A) vs
CR (B)
0.908 0.423 0.023* 0.441 0.570 0.547 0.181 0.151
Control (A) vs
CTC+CR (B)
0.807 0.024* 0.053 0.153 0.298 0.599 0.059 0.063
CTC (A) vs CR
(B)
0.193 0.633 0.508 0.269 0.808 0.691 0.058 0.065
CTC (A) vs
CTC+CR (B)
0.827 0.593 0.738 0.127 0.698 0.746 0.212 0.218
CR (A) vs CTC
+CR (B)
0.416 0.042* 0.227 0.008* 0.450 0.653 0.057 0.052
aP values marked with an asterisk are significantly different (P = 0.05).
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mucosa in mice not administered CTC at day 3 p.i. is
unknown, but is likely due to sampling variability as
there was no difference between the treatments in den-
sities of C. rodentium cells shed in feces at day 3 p.i. or
any other sample time.
We utilized mice that were reared under conditions in
which intestinal inflammation would be expected to be
exceptionally low (i.e. in the absence of inducers of
immune responses such as C. rodentium), and as such,
differential immunomodulation between the control and
CTC treatment would be expected to be minimal. How-
ever, we observed that the expression of the cytokine
genes IL-4 and TGF-b were markedly different in CTC
mice as compared to control animals on 21 day p.i. The
increase in IL-4 was both statistically and biologically
significant (i.e. two times greater than in control ani-
mals). Importantly, both CR infected and uninfected
mice that received CTC presented with modest to mark-
edly significant higher concentrations of IL-4 at clear-
ance relative to Control mice, thus suggesting that CTC
contributes to the differentiation of Th2 cells. Treat-
ment with therapeutic concentrations of tetracycline has
been observed to induce changes in IL-4 during both
acute and chronic disease by others. For example, Chirg-
win et al [33] reported that IL-4 expression was
decreased in tetracycline-treated Mongolian gerbils
infected with filarial nematodes. In contrast, IL-4 levels
in people infected with Orientia tsutsugamushi (incitant
of scrub typhus) and treated with tetracycline did not
change relative to background levels [34]. Although
therapeutic concentrations of tetracycline were used in
these two studies, their study highlighted the varied
responses that tetracycline treatment can have on Th2
cytokine expression within intestinal mucosa. The
greater than 50% decrease in TGF-b levels that we
observed in CTC mice relative to control mice (statisti-
cally and biologically significant) also indicates that the
intestine of CTC mice reduces numbers of Treg lym-
phocytes. The observed effects of CTC on IL-4 and
TGF-b are consistent with the immunomodulation
hypothesis of AGP action, a conclusion that is consis-
tent with the increased weight gain observed (i.e. a bio-
logical trend).
C. rodentium was chosen as an activator of inflamma-
tion and immunological function because it colonizes
the colon of mice and incites acute, self-limited colitis,
associated with progressive crypt hyperplasia in the dis-
tal colon [19,35]. Consistent with previous reports, there
were characteristic pathologic changes in mice inocu-
lated with C. rodentium, including thickening of the dis-
tal colon wall and crypt elongation attributed to
mucosal hyperplasia [36]. We measured changes in
intestinal morphology as opposed to weighing colons as
hypertrophy of the muscularis externa, deposition of
submucosal collagen (fibrosis), and infiltration of large
numbers of inflammatory cells can all cause marked
increases in colonic weight that are independent to
changes in the mucosa. In addition to hyperplasia, we
observed multifocal transmural inflammation and infil-
tration of inflammatory cells to the submucosa, muscu-
laris externa, and serosa, as documented previously
[22,37]. C. rodentium induces strong Th1 and Th17
cell-mediated immune responses [36,38-40], and there
were significant increases in transcript levels of both
Th1 (INF-g, TNF-a, IL-2) and Th17 (IL-17A, IL-22, IL-
1b, IL-6) cytokines in mice infected with the bacterium.
These effector T helper cell responses are important in
preventing and eliminating enteric bacterial infections.
Th17 cells have a crucial role in the clearance of extra-
cellular bacterial pathogens that are not adequately
handled by Th1 or Th2 responses [38,41], and Th1 cells
are needed to eliminate prolonged infections [42]. More-
over, morphological changes in the intestine, namely
increased enterocyte proliferation and turnover, were
associated with increased expression of the Th17 cyto-
kines, IL-17 [43] and IL-22 [44], an observation consis-
tent with the present study. One of the key observations
of this study was the time dependant activation of Th1
and Th17 of T helper cells. Based on differential expres-
sion of Th1 and Th17 cytokine profiles, we inferred
there was a temporal relationship in cytokine expression
necessary for eliminating infection by enteric pathogens,
such as C. rodentium. The initial increase in Th17 cyto-
kines may be needed to induce an effective immune
response, but could be inadequate to completely clear
an infection; therefore, subsequent induction of Th1
cytokines may be required to clear prolonged infections.
This trend has been observed in other enteric pathogen
and animal models. As an example, mice infected with
Salmonella enterica serovar Typhimurium had a marked
Th17 and Th1 response in the early and late stages of
infection, respectively [42].
Consistent with the immunomodulation hypothesis,
administration of a non-therapeutic dose of CTC
decreased C. rodentium-induced weight loss and miti-
gated pathologic changes, albeit in a modest manner.
For example, at 14 day p.i., mitotic activity was signifi-
cantly increased for the CR relative to the Control treat-
ment, but not for the CTC+CR relative to the Control
treatment. Similarly, crypt height, inflammatory infil-
trates, and the cumulative score were significantly
increased for the CR treatment, but not for the CTC
+CR treatment relative to the Control. Although the
reductions in weight loss and histopathologic changes
were relatively modest in CTC+CR relative to CR mice,
it is apparent that CTC treatment altered immune func-
tion as the changes observed in the intestine cannot be
explained by CR infection alone. Collectively, these
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observations are consistent with the immunomodulation
hypothesis. We also observed that the administration of
CTC (i.e. CTC+CR treatment) altered the expression of
cytokine genes involved in the acute phase of inflamma-
tion relative to the CR treatment. Concentrations of
Th1 cytokines were differentially expressed; IFN-g
mRNA were increased for the CTC+CR treatment at
the peak (i.e. day 8 p.i.) and late (i.e. day 14 p.i.) stages
of infection, whereas IL-2 mRNA was increased at clear-
ance (i.e. day 21 p.i.), and TNF-a mRNA was increased
at the peak stage and decreased at the late stage of
infection in mice administered CTC. Concentrations of
Th17 cytokines also were differentially expressed
between the CTC+CR and CR treatments; IL-17A
mRNA was decreased at day 14 p.i., IL-22 mRNA was
increased at day 8 p.i. and decreased at day 14 p.i., and
IL-1b mRNA was decreased at both days 8 and 14 p.i.
An acute-phase response can be triggered by an infec-
tious challenge; it is often characterized by release of the
pro-inflammatory cytokines, IL-1b, IL-6, and TNF-a,
which orchestrate behavioral, cellular, and metabolic
adjustments in the host that alter the partitioning of
nutrients away from growth and toward processes that
support the immune and inflammatory responses [14].
Furthermore, IFN-g, IL-1b and IL-6 facilitate TNF-a-
induced muscle cachexia [45]. Interestingly, CTC
administration only decreased expression of IL-17A
mRNA at the late stage of infection in the current
study, perhaps due to the concomitant down-regulation
of TNF-a and IL-1b mRNA expression. Since the Th17
cell response was amplified by TNF-a and IL-1b [46], it
is therefore likely that a decrease in TNF-a and IL-1b
expression will also decrease activation of Th17 cells.
Taken together, we conclude that reduced pathological
changes at the late stage of infection, as well as at clear-
ance, and the absence of weight loss at late infection in
inoculated mice that received CTC were due to up-reg-
ulation of IL-22 transcripts (i.e. a cytokine important in
mucosal defense) at the peak stage of infection, and
down-regulation of TNF-a, IL-1b, and IL-17A tran-
scripts (i.e. cytokines involved in inflammation, innate
and adaptive immunity) at the late stage of infection,
relative to inoculated mice not given CTC.
Our observations that a non-therapeutic concentration
of CTC given to mice modulated C. rodentium-induced
cytokine mRNA expression, ameliorated C. rodentium-
induced weight loss, and mitigated pathologic changes
associated with infection by C. rodentium, provided
experimental evidence in support of immunomodulation
as a primary mechanism of action of AGP in mammalian
livestock. There is additional evidence to support the
immunomodulation hypothesis. For example, oral admin-
istration of tetracycline reduced mortality rates and
inflammatory lesions associated with lipopolysaccharide
(LPS)-induced septic shock in mice by decreasing serum
concentrations of TNF-a [47]. Furthermore, tetracycline
inhibited LPS-induced secretion of TNF-a and IL-1b by
human monocytes in vitro [47]. Similarly, non-therapeutic
administration of tetracycline to experimentally stressed
poultry reduced immunologic stress by decreasing plasma
IL-1 concentrations [17]. Also consistent with the immu-
nomodulation hypothesis, Akunda et al. [48] reported that
a low concentration of CTC decreased TNF-a secretion
by cultured porcine Kupffer cells that were inoculated
with LPS. In addition, intra-peritoneal injection of low
doses of tetracycline and doxycycline decreased serum
concentrations of IL-1a and TNF-a in mice [49].
The generally accepted microbiota modulation hypoth-
esis of AGP action postulates that AGP modify the
microbiota, thereby reducing the deleterious impacts of
enteric bacteria on the host [12]. To measure impacts of
CTC on the mucosa-associated microbiota of the distal
colon, T-RFLP analysis was used. The T-RFLP method is
a medium to high resolution method that is commonly
used to compare bacterial communities in mammalian
intestines [50,51]. The composition of the intestinal
microbiota in association with mucosal surfaces can be
profoundly affected by inflammatory responses, and
sequence-based analysis (i.e. examining the partial 16S
rRNA gene) of mucosa-associated and luminal bacteria
in mice infected with C. rodentium revealed alterations
to the microbiota [52]. In contrast, we observed that C.
rodentium infection did not impart a profound effect on
the mucosa-associated microbiota of the murine distal
colon in the current study. Reasons for the discrepancies
between our study and that of Hoffmann et al. [52] are
speculative, but may be because they restricted their
examination to communities in the cecum and proximal
colon, and communities were only resolved at the phy-
lum or order level by pyrosequencing. Furthermore, they
did not measure inter-animal variability. Although pyro-
sequencing of communities has become prominent in
recent years, this platform is not a panacea; sequence
reads are currently limited to less than 450 bp thereby
limiting relevant sequence data to a small number of
variable regions of the 16S rRNA gene, which greatly
reduces the ability to discriminate amongst taxa, particu-
larly those that are closely related (e.g. at the species
level). One of the major advantages of T-RFLP is its abil-
ity to comparatively monitor treatment effects on the
microbiota in empirical models by obtaining measures of
inter-animal variability. It is possible that the inter-ani-
mal variability in the current study obscured subtle
effects of C. rodentium infection on the colonic micro-
biota. Alternatively, C. rodentium may not exert substan-
tive impacts on the microbiota of the distal colon, since
the bacterium does not colonize this region of the colon
throughout the entire infection period [53].
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Although CTC was given at a non-therapeutic con-
centration in the current study, it affected the composi-
tion of the microbiota, albeit inconsistently and in a
non-pronounced fashion. It has been reported that
administration of non-therapeutic CTC substantially
affected the composition of mucosa-associated micro-
biota in the ilea of piglets [54]. In contrast, it was
reported in a recent study that administration of virgi-
niamycin and tylosin to intensively raised swine at the
grow/finishing phase had no effect on bacterial commu-
nities in feces [27]. Furthermore, there was a high preva-
lence of bacteria that carried genes encoding resistance
to macrolide-lincosamide-streptogramin B (MLSB), from
which they attributed to the negligible impact of AGP
on the intestinal community [27]. We have similarly
observed that CTC and sulfamethazine, an AGP com-
monly administered to beef cattle, had no affect on the
luminal and mucosa-associated microbiota of the distal
small intestine and large intestine of beef cattle
(unpublished).
It is evident that both host genetics and environmental
factors can affect the intestinal microbiota. For example,
persons with gene mutations responsible for the autoin-
flammatory disorder, familial Mediterranean fever, pos-
sessed significantly different bacterial community
structures than healthy individuals, even when patients
were in remission [55]. Also, Altered Schaedler Flora
(ASF) mice of the same genetic background exhibited
significant variation in relative cell densities of the eight
ASF strains throughout the intestine when mice were
maintained in separate cages [56]. The inter-animal
variability encountered in the current and previous stu-
dies [54,56,57] further illustrates how difficult it is to
quantify the impact of a single variable in such a com-
plex system. Although CTC administration imparted a
modest effect on the composition of the microbiota in
the current study, it was not possible to definitively con-
clude whether this effect was direct or indirect. Consid-
ering a direct effect of CTC on the microbiota, it is
unclear how and to what degree subtle changes in the
microbiota caused by CTC would induce growth pro-
motion, especially given the complexity of the mechan-
isms involved and that AGP exert an effect in animals
with highly dissimilar microbiota. Since the indigenous
microbiota can influence C. rodentium pathogenesis
[22], even subtle changes in the microbiota may have
influenced immune responses to C. rodentium, further
illustrating the complexity of the interaction and the dif-
ficulty of elucidating specific effects.
Conclusions
The mucosa-associated microbiota of the murine colon
was not dramatically affected by C. rodentium, and was
inconsistently affected by oral administration of non-
therapeutic CTC. Furthermore, non-therapeutic CTC
administration modulated immune responses that were
temporally related to C. rodentium infection, in accor-
dance with the immunomodulation hypothesis of AGP
action. Although it was not possible to definitively ascer-
tain whether non-therapeutically administered CTC
directly or indirectly modulated the murine immune
system, we inferred that modulation of the microbiota
alone was not responsible. The current study not only
broadens our knowledge of how AGP may exert an
effect, it also emphasizes the necessity of examining
host responses interactively with the intestinal micro-
biota to elucidate the mechanisms of action of AGP.
Furthermore, an altered focus on strategies that modu-
late the enteric immune system as opposed to those that
modify the microbiota may lead to the development of
efficacious alternatives to AGP. Additional research is
required to further define the mechanisms of immuno-
modulation exerted by CTC and other AGP. In this
regard, studies utilizing gnotobotic animals in concert
with cell culture models are warranted, and such studies
have been initiated by our research group.
Methods
Inflammation incitant
C. rodentium (ATCC 51459) was transformed with a
gene that confers resistance to tetracycline. Plasmid
pMEK91, a Campylobacter shuttle vector that carries
the tetO gene [58], was modified (EcoRI digestion and
re-ligation) to remove the green fluorescent protein
gene. This vector was transferred into C. rodentium by
electroporation as previously described [59]. Electropo-
rated cells were incubated for 1 hour at 37°C and 100
rpm, plated on Luria-Bertani (LB) agar dishes containing
50 μg/mL tetracycline hydrochloride (Sigma, St. Louis,
MO), and incubated overnight at 37°C. To confirm
resistance to tetracycline in the transformed strain, a
minimum inhibitory concentration test was performed
as previously described for tetracycline hydrochloride
[5]; Escherichia coli (ATCC 25922) was used as the
quality control strain.
Mice and treatments
Forty eight female, 4-week-old C57BL/6J specific patho-
gen free (SPF) mice were purchased from Charles River
Laboratories International, Inc. (Montreal, QC). Mice
were housed at the small animal facility located at Agri-
culture and Agri-Food Canada Lethbridge Research
Centre (AAFC LRC). All requirements specified by the
Canadian Council on Animal Care were met, and the
project was approved by the LRC Animal Care Commit-
tee before commencement (Animal Use Protocol Review
0915). Mice were housed in sterilized, filter-topped
cages throughout the experiment, and maintained on a
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12 hour light/dark cycle. Mice were randomly assigned
to one of the following treatments: (i) no CTC, no
inoculation (Control); (ii) 32 mg/L CTC, no inoculation
(CTC); (iii) no CTC, C. rodentium inoculation (CR); and
(iv) 32 mg/L CTC, C. rodentium inoculation (CTC+CR).
The dose of CTC used in mice was extrapolated from
non-therapeutic doses administered to cattle. The ratio
of the non-therapeutic (75 mg/day) to therapeutic (6000
mg/day) doses of CTC in cattle is 1:80. By dividing the
average therapeutic dose in mice (i.e. 640 mg/L) by 80,
an estimated non-therapeutic dose for mice is 8 mg/L.
Since the average therapeutic dose in mice is approxi-
mately four fold higher than in cattle, the 8 mg/L dose
was multiplied by four to account for metabolic differ-
ences between the two animals, and thus a non-thera-
peutic dose of 32 mg/L of CTC was administered to
mice. Administration of CTC to mice commenced 3
weeks before inoculation with C. rodentium, and contin-
ued throughout the experimental period. CTC was
added to autoclaved drinking water, and fresh solutions
were provided twice weekly. Control and CR treatment
mice were provided with autoclaved water alone.
Sucrose (5% w/v; Sigma, St. Louis, MO) was added to
all water solutions to enhance palatability, and water
bottles were covered with aluminum foil.
Inoculation and maintenance of mice
To prepare inoculum, recombinant C. rodentium cells
were cultured in LB broth containing 50 μg/mL of tetra-
cycline for 16 hours at 37°C and 100 rpm, centrifuged
for 5 minutes at 1600 × g, the supernatant removed,
and the pelleted cells were resuspended in sterile phos-
phate buffer saline (PBS; 10 mM sodium phosphate buf-
fer, 130 mM sodium chloride; pH 7.2) to a final
concentration of 109 CFU/mL. Sodium bicarbonate (2%
w/v) was added to the inoculum. Mice (CR and CR
+CTC treatments) were inoculated with 100 μL (108
CFU) of the inoculum by oral gavage on two consecu-
tive days. Mice not inoculated with C. rodentium (Con-
trol and CTC treatments) were orally gavaged with an
equal volume of PBS containing 2% sodium bicarbonate
on the same days. Mice were provided with food and
water ad libitum, and were weighed twice weekly. In
addition, mice were monitored for signs of disease
according to the Animal Care Committee criteria for
stress assessment.
Collection of feces and tissues
Feces were collected aseptically from all mice once a
week for estimating residual CTC, and every second
day (commencing 1 day after the initial gavage) for
enumeration of C. rodentium. Mice were humanely
euthanized by anesthesia with isofluorane (Halocarbon
Products Corporation, River Edge, NJ) followed by
cervical dislocation 3, 8, 14, and 21 days post-inocula-
tion (p.i.), corresponding to the early, peak, late infec-
tion, and clearance periods, respectively [20]. Twelve
mice were euthanized at each time point (i.e. three
mice per treatment; n = 48 total). After euthanasia, a
midline incision was made, and the entire colon was
rapidly harvested and examined for alterations in
macroscopic appearance [36]. Four 1-cm sections from
the colon were then collected distally to cranially for
histology, quantification of cytokine mRNA expression,
characterization of mucosa-associated microbiota, and
C. rodentium enumeration, respectively. Colon samples
collected for histology were preserved in 10% buffered
formalin. Samples collected for RNA extraction were
inserted in sterile microcentrifuge tubes containing
RNAlater (Qiagen Inc., Mississauga, ON) and kept at
-20°C until processed; tissues were placed in RNAlater
within 2-3 min after death. To characterize the micro-
biota, the colonic section was opened longitudinally,
the mucosal surface gently rinsed with chilled sterile
PBS taking care not disrupt mucus, tissue samples
were aseptically removed with a sterile 3-mm-diameter
Biopsy Acu-Punch (CDMV, St. Hyacinthe, QC), and
samples were kept at -20°C until processed. Colonic
samples collected for enumeration of C. rodentium
were placed on ice immediately after collection, and
processed within 2 hours.
Estimation of residual CTC in murine feces
To estimate the concentration of residual CTC in fecal
samples, the basic agar diffusion method described pre-
viously was used [60]. Briefly, residual CTC was
extracted by suspending known amounts of feces (10-50
mg) in 0.01 N HCl. Feces were homogenized, the homo-
genate centrifuged (12,000 × g, 20 minutes), the super-
natant recovered (i.e. acidic extract) and sterilized by
filtration through a 0.2 μm filter (Nalgene, Rochester,
NY), and 50 μL of the sterile extract was added to indi-
vidual wells established with a cork borer (4-mm-diam)
in Tryptic Soy Agar (TSA; BD, Franklin Lakes, NJ) in
Petri dishes to which cells of Staphylococcus aureus
strain ATCC 29213 had been distributed over the agar
surface. S. aureus cells were obtained from an overnight
culture on TSA at 37°C, cells were suspended in Colum-
bia broth (BD), cell density adjusted to an optical den-
sity (OD) equivalent to a 0.5 McFarland standard (OD
of 0.1 at 600 nm), and 100 μL aliquot of the cell suspen-
sion spread on TSA. Assays were carried out in tripli-
cate for each sample. Zones of inhibition in the S.
aureus lawn were measured after 18 hours at 37°C,
using a Biomic V3 Image Analyzer (Giles Scientific
USA, Santa Barbara, CA), with slight adjustments per-
formed by hand. Estimation of CTC concentrations in
fecal samples was interpolated from a standard curve
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obtained by measuring zones of inhibition from known
concentrations of acidified CTC.
Enumeration of C. rodentium
Densities of C. rodentium cells were determined by
homogenizing feces or colonic samples in Columbia
broth, and spreading serial dilutions of the homogenate
onto MacConkey agar (BD). Cultures were incubated
overnight at 37°C, enumerated at the dilution yielding
30-300 CFU/dish, and adjusted by weight. C. rodentium
colonies were identified based on morphology [61], and
representative colonies exhibiting characteristic mor-
phology (i.e. an average of three colonies per dish) were
subcultured to confirm their identity and the presence
of the tetO gene by PCR. Reaction mixtures for PCR
consisted of 2 μL of a suspension of cells in 20 μL of
Optima water, 1X PCR buffer, 0.2 mM of each deoxynu-
cleoside triphosphate, 0.1 μg/μL of acetylated bovine
serum albumin (Promega, Madison, WI), 0.625 Units of
Taq DNA polymerase (Qiagen Inc.), 0.5 μM of each pri-
mer, and Optima water to a final volume of 20 μL. For
C. rodentium identification, the Cr-espB-f (5’-
AAGTCTGTCAATACCGCCTC-3’) and Cr-espB-r (5’-
AATGTGCCAACTGTCTCATC-3’) primers were used
[62]. For tetO gene detection, the tetO-F-PstI (5’-TAA
CTG CAG AGA TTC AGT ATT ATA ACA AGG-3’),
and tetO-R-PstI (5’-TTA CTG CAG CAT CAT AAT
TAT CTC TAA TCC-3’) primers were used [58].
Histopathology
Tissue samples were maintained in 10% buffered forma-
lin for a minimum of 4 hours and for a maximum of 2
weeks. Tissue samples were dehydrated with ethanol
and Histoclear (Fisher Scientific Inc.), and paraffinized
with Paraplast Plus (Fisher Scientific Inc.) for 2 hours at
60°C in a vacuum oven. Samples were embedded using
a Shandon Histocentre III (Fisher Scientific Inc.), sec-
tioned (4 μm) using a Finesse 325 microtome (Fisher
Scientific Inc.), and sections were placed on Superfrost
Plus Gold slides (Fisher Scientific Inc.). Sections were
deparaffinized with xylene, stained with hematoxylin
and eosin (H&E) following a standard protocol, and
examined with a Zeiss Axioskop III (Carl Zeiss Canada
Ltd., Toronto, ON). Images were captured using an
Axiocam camera (Carl Zeiss Canada Ltd.). Histological
inflammation scoring was performed in a “blinded” fash-
ion (i.e. as to treatment) by a veterinary pathologist,
with scoring criteria adapted from previously described
methods [19,63]. Colonic sections were graded 0 to 4
for epithelial cell hyperplasia, crypt height, epithelial
injury, extent of inflammatory infiltrates, and 0 to 3 for
mitotic activity of epithelial cells, and goblet cell deple-
tion. The total pathology score was obtained by calculat-
ing the sum of scores for all categories for each mouse.
Epithelial hyperplasia caused by C. rodentium (i.e. crypt
height) was quantified by calculating the average of ten
measurements of well-oriented crypts for each section.
Quantification of mRNA expression of cytokine genes
Total RNA was extracted from colonic tissues with TRI-
zol reagent (Invitrogen Corp., Carlsbad, CA) according
to the manufacturer’s recommendations. Residual geno-
mic DNA contamination was removed using a DNA
purification protocol from RNeasy kit (Qiagen Inc.).
After quantification on an Ultrospect 3100 pro UV/Visi-
ble spectrophotometer (General Electric Healthcare, Pis-
cataway, NJ), 1 μg of total RNA was reverse transcribed
into cDNA using the RT2 First Strand Kit (SABios-
ciences Corp., Frederick, MD). Quality assurance and
control of total RNA was performed with the RT2 RNA
QC PCR Arrays Kit. A custom RT2 Profiler PCR Array
System (SABiosciences Corp.) was used to quantify the
mRNA expression of the following cytokines: interleukin
(IL)-1b, IL-2, tumor necrosis factor (TNF)-a, interferon
(IFN)-g, IL-6, IL-4, IL-10, IL-17A, IL-22, and transform-
ing growth factor (TGF)-b1. Two housekeeping genes,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
and actin-b were used to provide an estimate of the
range of threshold cycles to be expected in subsequent
PCR array analyses. The housekeeping gene that pre-
sented the least variation of expression among samples
with the quality control kit was used to normalize the
data. Real-time PCR was performed using an MxPro
3005 thermocycler (Agilent Technologies, Santa Clara,
CA). Expression was normalized against GAPDH, and
data were log-transformed (i.e. log [2-ΔCt + 1]) for statis-
tical analysis.
Characterization of bacterial communities
Total genomic DNA was extracted from colonic samples
using the Gram-positive bacteria protocol of the DNeasy
Blood and Tissue Kit (Qiagen Inc.). Amplification of the
16S rRNA genes for terminal restriction fragment length
polymorphism (T-RFLP) analysis, restriction of amplified
rRNA genes, capillary gel electrophoresis, and fragment
size determination, were conducted as performed as pre-
viously described [51]. Selection of terminal restriction
fragments (T-RFs) (i.e. “true peaks”) was performed with
T-REX software [64].
Statistical analyses
The experiment was designed as a randomized complete
block design (2 × 2 factorial) with: (i) two levels of treat-
ment (i.e. CTC or no CTC, and C. rodentium or no C.
rodentium); (ii) four (i.e. for C. rodentium CFU asso-
ciated with colonic mucosa, cytokine mRNA transcrip-
tion, and colonic crypt height), six (i.e. for murine body
weights), or eleven (i.e. for C. rodentium CFU in murine
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feces) levels of time; and (iii) three levels of block as the
three replicates were conducted on separate occasions
and thus were independent. All analyses were conducted
using SAS (SAS Institute Inc., Cary, NC). For parametric
data (i.e. CFU counts in feces and colon, murine weight,
and cytokine mRNA expression), analysis of variance
was performed using the MIXED procedure with treat-
ment one (i.e. CTC or no CTC), treatment two (i.e. C.
rodentium or no C. rodentium), time, and their interac-
tion, included in the model as fixed effects. Differences
among means of interest were compared through the
generation of least-square means with Fisher’s protected
least significant difference test. For C. rodentium CFU
counts in feces and murine body weights, the repeated-
measurement statement was applied, and the appropri-
ate error structure was determined using Akaike’s infor-
mation criterion and the Bayesian information criterion.
In all instances, the UNIVARIATE procedure was used
to produce normal probability plots to confirm normal-
ity and to identify outliers, which were removed before
completion of the final analysis. For non-parametric
data (i.e. histological inflammation scoring data for indi-
vidual category scores and total scores), the NPAR1-
WAY procedure with the Wilcoxon scores (rank sums)
for variable score and one-sided Wilcoxon two-sample
test were performed. For analysis of T-RFLP data, T-RF
matrices produced by the T-REX software were
imported into Bionumerics (Applied Maths, Inc., Austin,
TX) for cluster analyses and group significance determi-
nation as described previously [51]. Cluster analysis was
performed using the Dice coefficient, and non-metric
multi-dimensional scaling analysis (NMS) of the similar-
ity matrices was performed using SAS (SAS Institute
Inc.). For all analyses, P < 0.05 was considered
significant.
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